Each ml contains Brimonidine Tartrate INN 2 mg.
Topical administration of brimonidine decreases intraocular pressure (IOP) in humans. When used as directed, brimonidine ophthalmic solution reduces elevated IOP with minimal effect on cardiovascular parameters.
Brimonidine has a rapid onset of action, with the peak ocular hypotensive effect occurring at approximately 2 hours post-dosing. The duration of effect is 12 hours or greater.
Fluorophotometric studies in animals and humans suggest that brimonidine has a dual mechanism of action. Brimonidine lowers IOP by reducing aqueous humor production and increasing uveoscleral outflow.
If more than one topical ophthalmic medicine is to be used, other eye drops should not be used within 5 to 10 minutes of using this eye drops.
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Brimonidine ophthalmic solution 0.2% should be used with caution in patients with known hypersensitivity to other alpha-adrenoceptor agonists.
Although brimonidine had minimal effect on blood pressure and heart rate of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.
Brimonidine has not been studied in patients with hepatic or renal impairment; caution should be exercised in treating such patients.
Brimonidine should be used with caution in patients with depression, cerebral or coronary insufficiency.
Brimonidine has not been studied in pregnant women. Studies in animals have shown that brimonidine crosses the placenta, but very high doses have not been shown to cause harmful effects in the fetus.
It is not known whether brimonidine passes into human breast milk. However, it has been shown to pass into the milk of nursing animals.
Keep out of reach of children.
Do not use more than 4 weeks after opening.